Stifel reiterates Buy on PMI Group stock after FDA authorization

🌐 Investing.com (CY) —
Stifel reiterates Buy on PMI Group stock after FDA authorization

AI Summary

Stifel reiterated a Buy rating on PMI Group stock following FDA authorization, reflecting positive regulatory developments and enhanced market outlook. This supports investor confidence in the company’s prospects.

Markets Deals Health PMI Group stock rating Stifel FDA authorization regulatory approval

Read original source →